Doxorubin 50

Doxorubin 50 is a prescription anticancer injection containing Doxorubicin Hydrochloride 50 mg. It is supplied as a lyophilized vial and is meant for IV use only, as shown on the pack. This is a chemotherapy medicine used only under specialist supervision, because this is very much not the kind of vial anyone should “try casually.”

Doxorubicin is an anthracycline chemotherapy medicine used in the treatment of several cancers, including breast cancer, leukemias, lymphomas, ovarian cancer, bladder cancer, thyroid cancer, sarcomas, and other doctor-directed oncology conditions.

Composition:

Doxorubicin Hydrochloride – 50 mg

Key Information:

Brand Name: Doxorubin 50
Strength: 50 mg
Active Ingredient: Doxorubicin Hydrochloride
Dosage Form: Injection / Lyophilized powder
Medicine Type: Anticancer medicine / Chemotherapy / Anthracycline antibiotic
Manufacturer/Brand Shown: Khandelwal Laboratories Pvt. Ltd.
Common Use: Treatment of selected cancer conditions
Administration: IV use only
Category: Prescription medicine
Pack Size: 50 mg vial

How It Works:

Doxorubin 50 works by interfering with cancer cell DNA activity. Doxorubicin interacts with DNA and topoisomerase II, which can prevent cancer cells from multiplying and may lead to cancer cell death. Tiny vial, giant molecular sabotage operation.

Potential Indications:

• Breast cancer
• Acute lymphoblastic leukemia
• Acute myeloblastic leukemia
• Hodgkin’s disease
• Non-Hodgkin lymphoma
• Ovarian cancer
• Bladder cancer
• Thyroid cancer
• Bone and soft tissue sarcomas
• Other oncologist-directed cancer treatment plans

Dosage & Storage:

Use only as directed by a qualified oncologist or healthcare professional.
This injection should be reconstituted, diluted, and administered only by trained medical staff.
Do not self-administer.
Doxorubicin is administered intravenously, and dosing depends on cancer type, body surface area, previous treatment, liver function, and the chemotherapy regimen. Official labeling lists IV dosing schedules such as 60–75 mg/m² every 21 days as a single agent or 40–75 mg/m² every 21–28 days in combination therapy, but the final dose must be decided by the treating doctor.
Store as per the product label and hospital pharmacy instructions.
Keep out of reach of children.

Important Safety Information:

Doxorubicin should be used only under strict medical supervision. It may affect the heart, bone marrow, liver, and blood counts, so regular monitoring is usually required during treatment. Official labeling warns to discontinue doxorubicin if signs or symptoms of cardiomyopathy develop.

Possible side effects may include:

• Nausea
• Vomiting
• Hair loss
• Mouth sores
• Tiredness or weakness
• Low blood cell counts
• Increased risk of infection
• Increased bleeding risk
• Red/orange urine discoloration after treatment
• Injection-site reaction
• Heart-related complications
• Liver-related problems

Serious symptoms such as chest pain, breathing difficulty, swelling, fever, unusual bleeding, severe mouth ulcers, black stools, severe weakness, or signs of infection should be reported to a doctor immediately.

Label Verification:

Please double-check the physical product label before listing or use, including product name, strength, active ingredient, manufacturer details, batch number, expiry date, storage instructions, reconstitution instructions, dosage directions, and route of administration.

General Information Disclaimer:

The information provided here is for general educational and product-identification purposes only. It should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication regimen.